How One Expert's Exceptional Skills Are Accelerating Life-Saving Treatments As the director of statistical programming and biostatistics at Epis Data Inc., Srinivasa Reddy Mukkala accelerates life-saving treatments, especially gene therapy. He has worked in the pharmaceutical industry for over 15 years.
Opinions expressed by BIZ Experiences contributors are their own.
You're reading BIZ Experiences India, an international franchise of BIZ Experiences Media.
The difficulty of modern drug development can be staggering, with only 1 in 5,000 compounds making it from the lab to patients. In this challenging space, Srinivasa Reddy Mukkala is streamlining the journey from clinical trials to approval, potentially saving years in the development process and bringing critical treatments to patients.
As the director of statistical programming and biostatistics at Epis Data Inc., Srinivasa Reddy Mukkala accelerates life-saving treatments, especially gene therapy. He has worked in the pharmaceutical industry for over 15 years.
"In my industry, every day counts," Srinivasa Reddy Mukkala says. "I always aim to improve processes and data quality to bring life-changing treatments to patients faster, while maintaining safety and efficacy."
Pharmacy, Chemistry, and Data Science: An Exceptional Skill Set
Srinivasa Reddy Mukkala's education is varied and impressive. He has a bachelor's degree in pharmacy from The Tamil Nadu Dr. M.G.R. Medical University, a master's degree in chemistry and biochemistry from Lamar University, and a master's degree in information systems. This education allows him to connect scientific understanding with data-driven decisions.
This rare mix of skills allows him to handle clinical trials and drug development from many angles. He understands pharmacology and chemistry deeply, which helps him grasp drug mechanisms and potential interactions.
"My background in pharmacy and chemistry helps me understand the data we analyze. I can see how these compounds interact with the body and what that means for patients," he explains.
How Srinivasa Reddy Mukkala Leads Gene Therapy Progress
Srinivasa Reddy Mukkala has become an important figure in gene therapy, a new way to treat genetic disorders. He has helped develop and approve several new gene therapies, including Zynteglo for beta-thalassemia and Lyfgenia for sickle cell disease.
Mukkala's skills are especially useful in navigating the complex rules of gene therapies. His understanding of Food and Drug Administration (FDA) requirements and submission processes has helped speed up the approval of these life-saving treatments. For example, Srinivasa Reddy Mukkala was key in submitting Zynteglo, which the FDA approved in August 2022.
"Gene therapy is truly changing how we treat genetic disorders," he says. "These complex treatments need very careful data analysis and submission. After all, we are reprogramming genes. The stakes are very high."
Contributions to Submission Processes
Srinivasa Reddy Mukkala has been important in improving and standardizing submission processes for new drug applications. As a Clinical Data Interchange Standards Consortium (CDISC.org) Wiki Analysis Standards Development team member, Mukkala helps create and refine standards for FDA submissions.
His knowledge of the Study Data Tabulation Model (SDTM) and the Analysis Dataset Model (ADaM) has been very influential. These standardized frameworks for organizing and analyzing clinical trial data are now essential in the industry, helping ensure consistency and quality across studies and submissions.
Srinivasa Reddy Mukkala's work on submissions goes beyond just following rules. "We create a story with the data," he explains. "When we submit to the FDA, we show the drug's effectiveness and safety clearly and thoroughly."
Accelerating Drug Development: Skills in Clinical Trial Data Analysis and Submission
Mukkala's impact on drug development goes beyond gene therapies. His main strength is his ability to connect complex statistical analyses with clinical uses. His work has helped pharmaceutical companies find problems earlier in development, saving time and resources while improving patient safety.
For instance, Srinivasa Reddy Mukkala's contributions were especially important in developing Omadacycline (NUZYRA), an antibiotic the FDA approved in 2018 to treat community-acquired bacterial pneumonia and acute bacterial skin infections.
Creating a Path for Future Treatments
Srinivasa Reddy Mukkala focuses on advancing treatments for rare diseases, for which his special skills are very valuable. He is particularly excited about using personalized medicine to treat rare diseases. His data analysis and statistical programming help identify patterns and biomarkers that could lead to more targeted and effective treatments.
"When it comes to rare diseases, each patient is different," Mukkala notes. "When you study large amounts of genetic and clinical data, you can create treatments for individual patients, maximizing effectiveness while minimizing side effects."
When discussing future plans, Mukkala emphasizes improving industry collaboration and data sharing. He believes open research can accelerate treatment development, particularly for rare diseases. "Every day, we get closer to treatments we once thought impossible," he notes.
